Contineum Therapeutics公司宣布,其研发的Pipe-791在1B期临床试验中成功达到安全性及耐受性的主要研究终点。这一重要进展为后续临床开发奠定了坚实基础。
Contineum Therapeutics公司宣布,其研发的Pipe-791在1B期临床试验中成功达到安全性及耐受性的主要研究终点。这一重要进展为后续临床开发奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.